文献速递临床试验与 GCP

75毫克与150毫克阿司匹林预防高危女性早产型子痫前期的比较:三级医院随机双盲临床试验研究方案

Comparison of 75 mg versus 150 mg aspirin for the prevention of preterm preeclampsia in high-risk women at a tertiary level hospital: study protocol for a randomized double-blind clinical trial.
PubMed 文献 · Trials · 2024-10-15

本随机双盲临床试验旨在比较75毫克与150毫克阿司匹林在高危女性中预防早产型子痫前期的疗效与安全性。纳入18-45岁、孕12-16周、单胎、筛查阳性的女性,按1:1随机分组,每晚服用阿司匹林至孕37周或发生早产型子痫前期。基于两组预期比例的样本量计算为370例(每组185例),并考虑20%的脱落率。

要点

  • 研究比较75毫克与150毫克阿司匹林预防高危女性早产型子痫前期的疗效与安全性。
  • 纳入18-45岁、孕12-16周、单胎、筛查阳性的女性,按1:1随机分组。
  • 样本量计算为370例(每组185例),并考虑20%的脱落率。

核心结论

  • 本研究旨在比较两种剂量阿司匹林(75毫克与150毫克)在高危女性中预防早产型子痫前期的有效性与安全性,其结果可能影响临床实践并促进循证产科护理。

研究设计与样本

  • 前瞻性随机双盲临床试验,计划纳入370例(每组185例)18-45岁、孕12-16周、单胎、筛查阳性的女性,按1:1随机分配至75毫克或150毫克阿司匹林组。

主要发现

  • 待研究结果报告;本方案未提供疗效或安全性比较数据。

关键数值与推荐

  • 纳入标准:年龄18-45岁、单胎妊娠、孕周12至16周、筛查阳性。
  • 干预:每晚服用阿司匹林75毫克或150毫克,直至孕37周或发生早产型子痫前期(以较早者为准)。
  • 主要结局包括早产型子痫前期发生率及母婴并发症。
  • 样本量:370例(每组185例),考虑20%脱落率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive disorders of pregnancy (HDP) pose significant risks to maternal and fetal health, with substantial mortality and morbidity rates globally, particularly in developing countries. Pre-eclampsia (PE) accounts for a notable portion of maternal morbidity and mortality, with varied prevalence across regions within countries like India. Despite advancements, disparities in healthcare access persist, influencing outcomes. PE not only affects maternal health during pregnancy but also predisposes women to long-term cardiovascular complications, emphasizing the need for early screening and preventive measures. METHODS: This prospective randomized double-blind clinical trial aims to compare the efficacy and safety of 75 mg versus 150 mg aspirin for preventing preterm pre-eclampsia in high-risk women. Screen-positive women aged 18-45 years with singleton pregnancies between 12 and 16 weeks of gestational age will be enrolled. They will be randomized in a 1:1 ratio to receive either 75 mg or 150 mg of aspirin nightly until 37 weeks of pregnancy or earlier if preterm pre-eclampsia develops. Feto-maternal outcomes, including preterm pre-eclampsia incidence and neonatal and maternal complications, will be assessed. The sample size calculation based on expected proportions of preterm pre-eclampsia in both groups indicates a total of 370 participants (185 per group) accounting for 20% attrition. DISCUSSION: This prospective randomized double-blind clinical trial aims to compare the effectiveness and safety of two doses of aspirin (75 mg vs 150 mg) in preventing preterm pre-eclampsia in high-risk women. The potential implications of this study are significant, including the optimization of aspirin prophylaxis, the development of evidence-based guidelines, and comprehensive assessment of maternal and fetal outcomes. In conclusion, the results of this study have the potential to significantly impact clinical practice by enhancing maternal and perinatal health outcomes and contributing to evidence-based obstetric care. TRIAL REGISTRATION: Clinical Trials Registry-India CTRI/2023/12/060983. Trial was registered prospectively on 29 December 2023. Acknowledgement Number REF/2023/12/076358. https://acrobat.adobe.com/id/urn:aaid:sc:AP:15870322-f1f4-4460-900c-6e056ab83a44 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Saxena U, Lachyan A, Goyal C, et al. Comparison of 75 mg versus 150 mg aspirin for the prevention of preterm preeclampsia in high-risk women at a tertiary level hospital: study protocol for a randomized double-blind clinical trial. Trials. 2024. PMID: 39402669. doi:10.1186/s13063-024-08520-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。